Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 133

  • Showing results for hippe e. Search instead for Hippke E (1 item)
1.

[Let the patients speak].

Hippe E.

Ugeskr Laeger. 2011 Feb 21;173(8):600. Danish. No abstract available.

PMID:
21434457
2.

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma.

Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J; EORTC Quality of Life Group.

Eur J Cancer. 2007 Jul;43(11):1670-8. Epub 2007 Jun 15.

PMID:
17574838
3.

Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care.

Hippe E, Westin J, Wislöff F.

Eur J Haematol. 2005 Mar;74(3):185-93. Review.

PMID:
15693787
4.

[Overuse of vitamin B12 preparations].

Hippe E.

Ugeskr Laeger. 2003 May 5;165(19):1965. Danish. No abstract available.

PMID:
12795068
5.
6.

Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.

Gulbrandsen N, Wisløff F, Brinch L, Carlson K, Dahl IM, Gimsing P, Hippe E, Hjorth M, Knudsen LM, Lamvik J, Lenhoff S, Løfvenberg E, Nesthus I, Nielsen JL, Turesson I, Westin J; Nordic Myeloma Study Group.

Med Oncol. 2001;18(1):65-77.

PMID:
11778972
7.

Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.

Knudsen LM, Hjorth M, Hippe E.

Eur J Haematol. 2000 Sep;65(3):175-81.

PMID:
11007053
8.

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.

Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wislöff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen HE, Lamvik J, Löfvenberg E, Nesthus I, Rödjer S.

Blood. 2000 Jan 1;95(1):7-11. Erratum in: Blood. 2010 Sep 30;116(13):2402. Johnsen, H [corrected to Johnsen, H E].

9.
10.

[Gastric carcinoid tumor in pernicious anemia].

Meyer D, Brynskov J, Federspiel BH, Hippe E.

Ugeskr Laeger. 1998 Jun 29;160(27):4077-9. Danish.

PMID:
9659840
12.
13.

Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.

Wisløff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J.

Br J Haematol. 1996 Mar;92(3):604-13.

PMID:
8616024
14.

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia.

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Haemostasis. 1996;26 Suppl 1:159-64.

PMID:
8904193
15.

Cobalamin and cobalamin-binding proteins in plasma related to the clinical condition in chronic myelogenous leukemia.

Gimsing P, Overballe-Petersen C, Hippe E.

Leukemia. 1995 Sep;9(9):1604-9. No abstract available.

PMID:
7658734
17.

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.

Juliusson G, Heldal D, Hippe E, Hedenus M, Malm C, Wallman K, Stolt CM, Evensen SA, Albertioni F, Tjønnfjord G, et al.

J Clin Oncol. 1995 Apr;13(4):989-95.

PMID:
7707128
18.

Thyroid function and autoimmunity in pernicious anemia before and during cyanocobalamin treatment.

Ottesen M, Feldt-Rasmussen U, Andersen J, Hippe E, Schouboe A.

J Endocrinol Invest. 1995 Feb;18(2):91-7.

PMID:
7629393
19.

Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group.

Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J.

Eur J Haematol. 1994 Oct;53(4):207-12.

PMID:
7957804
20.

[Coagulation factor VII--new physiopathological and therapeutic aspects].

Helleberg C, Hippe E, Ingerslev J.

Ugeskr Laeger. 1994 Aug 22;156(34):4805-10. Review. Danish.

PMID:
7992413

Supplemental Content

Support Center